Journal of cardiac failure
-
Randomized Controlled Trial
A 6-month follow-up of intermittent levosimendan administration effect on systolic function, specific activity questionnaire, and arrhythmia in advanced heart failure.
Levosimendan (LS) improves cardiac contractility without increasing myocardial oxygen demand. We administrated LS on a monthly intermittent 24-hour protocol and evaluated the clinical effect after 6 months in a randomized, open, prospective study. ⋯ A 6-month intermittent LS treatment in patients with decompensated advanced heart failure improved symptoms and LV systolic function.